Cover Image
市場調查報告書

肝硬化的全球市場:2016∼2020年

Global Liver Cirrhosis Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357747
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
肝硬化的全球市場:2016∼2020年 Global Liver Cirrhosis Market 2016-2020
出版日期: 2016年05月06日 內容資訊: 英文 74 Pages
簡介

肝硬化是肝臟組織損傷等造成肝臟停止適當機能的嚴重症狀。由長期曝露於病感染或酒精等毒素引起。此外慢性肝炎病毒及非酒精性脂肪肝炎也是肝硬化的原因。全球肝硬化市場在2016∼2020年這段期間預測將以年複合成長率4.36%擴大。

本報告提供全球肝硬化市場現狀與到2020年前的成長預測,彙整市場趨勢與課題,各地區趨勢,主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 對疾病的認識
  • 病因
  • 症狀
  • 病理學
  • 診斷
  • 流行病學
  • 預防
  • 治療
  • 酒精消費肝硬化帶來的影響

第6章 產品研發線

  • 開發平台候補資訊
  • 臨床實驗

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各分子類型市場區隔

  • 生技藥品
  • 小分子

第9章 肝硬化的各類型市場區隔

第10章 肝硬化治療的各類型市場區隔

  • 肝硬化原因的治療
  • 肝硬化併發症的治療

第11章 各地區市場市場區隔

  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第12章 推動市場的要素巷

  • 肝硬化的高罹患率
  • 技術的進步
  • 高醫療未滿足需求
  • 生活方式的變化

第13章 促進要素的影響

第14章 市場課題

  • 替代療法的使用
  • 藥物的副作用
  • 患者不徹底遵守
  • 嚴格的法律規章指南

第15章 促進要素與課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • F Hoffmann-La Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

圖表

目錄
Product Code: IRTNTR8209

About Cirrhosis of the Liver

Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

Technavio's analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck

Other Prominent Vendors

  • Bristol-Myers Squibb
  • Conatus Pharmaceuticals
  • Gwo Xi Stem Cell Applied Technology
  • Instituto Grifols
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine
  • Pharmicell
  • Salix Pharmaceuticals
  • Stempeutics Research

Market driver

  • High prevalence of liver cirrhosis
  • For a full, detailed list, view our report

Market challenge

  • Adverse effects of drugs
  • For a full, detailed list, view our report

Market trend

  • Use of off-label drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Etiology
  • Symptoms
  • Pathophysiology
  • Diagnosis
  • Epidemiology
  • Prevention
  • Treatment
  • Impact of alcohol consumption on liver cirrhosis

PART 06: Pipeline portfolio

  • Information on pipeline candidates
  • Clinical trials for liver cirrhosis

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 09: Market segmentation by types of liver cirrhosis

PART 10: Market segmentation by types of liver cirrhosis treatment

  • Medications to treat causes of liver cirrhosis
  • Medications to treat complications of liver cirrhosis

PART 11: Geographical segmentation

  • Liver cirrhosis medication market in Americas
  • Market overview
  • Market size and forecast
  • Liver cirrhosis medication market in EMEA
  • Market overview
  • Market size and forecast
  • Liver cirrhosis medication market in APAC
  • Market overview
  • Market size and forecast

PART 12: Market drivers

  • High prevalence of liver cirrhosis
  • Advances in technology
  • High unmet medical needs
  • Changes in lifestyle

PART 13: Impact of drivers

PART 14: Market challenges

  • Use of alternative therapies
  • Adverse effects of drugs
  • Poor patient adherence
  • Stringent regulatory guidelines

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Rise in public awareness
  • Increase in R&D
  • Use of off-label drugs
  • Patient assistance programs

PART 17: Vendor landscape

  • Competitive scenario
  • F Hoffmann-La Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Stages of liver diseases
  • Exhibit 03: Causes of liver cirrhosis
  • Exhibit 04: Diagnosis of liver cirrhosis
  • Exhibit 05: Effect of alcohol consumption on liver cirrhosis
  • Exhibit 06: Pipeline molecules for liver cirrhosis
  • Exhibit 07: Clinical trials by development phase
  • Exhibit 08: Clinical trials by trial status
  • Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions)
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Four main types of liver cirrhosis
  • Exhibit 12: Market share by types of liver cirrhosis
  • Exhibit 13: Types of treatment for liver cirrhosis
  • Exhibit 14: Global liver cirrhosis medication market segment by geography 2015
  • Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions)
  • Exhibit 16: Liver cirrhosis medication market in Americas ($ millions)
  • Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions)
  • Exhibit 18: Liver cirrhosis medication market in APAC ($ billions)
  • Exhibit 19: Impact of drivers
  • Exhibit 20: Impact of drivers and challenges
  • Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue
  • Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
  • Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
  • Exhibit 25: F Hoffmann-La Roche: Key takeaways
  • Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
  • Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014
  • Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
  • Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
  • Exhibit 33: Gilead Sciences: Key takeaways
  • Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014
  • Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014
  • Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
  • Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
  • Exhibit 39: Johnson & Johnson: Key takeaways
  • Exhibit 40: Merck: Business segmentation by revenue 2014
  • Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 42: Merck: Geographical segmentation by revenue 2014
  • Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
  • Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
  • Exhibit 45: Merck: Key takeaways
Back to Top